<DOC>
	<DOCNO>NCT02994498</DOCNO>
	<brief_summary>The primary study objective 1. evaluate safety tolerability profile DCB-BO1301 determine maximum tolerate dose ( MTD ) DCB-BO1301 add-on therapy dacarbazine subject advance melanoma ( Phase I ) 2. evaluate efficacy profile DCB-BO1301 MTD low dose level add-on therapy dacarbazine subject advance melanoma term progression free survival ( Phase IIa )</brief_summary>
	<brief_title>DCB-BO1301 Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Subjects ≧ 20 year old ( inclusive ) 2 . Histologically cytologically confirm advanced melanoma , ( stage III IV ) 3 . Subject must least one follow : Melanoma previously treat least one complete partial course therapy melanoma either poor response evidence disease progression ; Melanoma treat firstline therapy medical comorbidities/risk toxicity ; Melanoma treat firstline therapy patient refusal . 4 . If melanoma possibly resectable , melanoma must recur despite least two attempt resection . 5 . Evaluable disease , least one measurable target lesion image RECIST 1.1 criterion previous scan 6 . ECOG performance status ≤ 2 life expectancy ≥ 3 month Note : ECOG = Eastern Cooperative Oncology Group 7 . Females subject must either nonchildbearing potential : Or , childbearing potential : Must negative urine serum pregnancy test screening , If heterosexually active , must use least 1 form birth control ( must barrier method ) start screen primary study period . 8 . Female subject must breastfeed screening , treatment period primary study period . 9 . Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screening , treatment period primary study period . 10 . Dated sign informed consent 1 . Primary CNS malignancy clinically active CNS metastases 2 . Ascertained hypersensitivity component investigational product standard therapy subject treat 3 . Any following hematologic abnormality : 1 . Hemoglobin &lt; 10 g/dL , 2 . ANC &lt; 1,500/μL , 3 . Platelets &lt; 75,000 /μL Note : ANC = absolute neutrophil count 4 . Any following serum chemistry abnormality : 1 . Total bilirubin &gt; 1.5 × ULN , 2 . AST , ALT , AlkP &gt; 2.5 × ULN , 3. serum albumin &lt; 2.5 g/dL , 4. creatinine &gt; 1.5 × ULN , 5. creatine phosphokinase ( CPK ) &gt; 2.5 × ULN , d. ≥ Grade 3 laboratory abnormality baseline ( list ) Note : ULN = upper limit normal . AST = aspartate transaminase , ALT = alanine transaminase 5 . History known brain metastasis 6 . Anticipated requiring , take , take past 2 week Screening visit systemic steroid , immunosuppressive agent , aspirin ( 100 mg/day ) , NSAID ( except COX2 Inhibitors ) , heparin , low molecular weight heparin warfarin ( 1 mg/day ) Note : NSAID = Nonsteroidal antiinflammatory drug 7 . Uncontrolled nausea vomit symptom would prevent ability comply daily oral DCBBO1301 treatment 8 . Serious/active infection HIV , HBV HCV carrier , infection require parenteral antibiotic Note : HIV = Human immunodeficiency virus ; HBV = Hepatitis B virus ; HCV = hepatitis C virus 9 . Uncontrolled psychiatric disorder alter mental status precluding inform consent necessary test 10 . Consumption herbal preparations/supplements ( except daily multivitamin/mineral supplement contain herbal component ) within 2 week prior start DCBBO1301 administration 11 . Significant cardiovascular disease , include : 1 . Active clinically symptomatic leave ventricular failure 2 . Active hypertension ( diastolic blood pressure &gt; 100 mmHg ) . Subjects history hypertension must stable dos antihypertensive drug ≥ 4 week prior start DCBBO1301 administration 3 . Uncontrolled hypertension : Blood pressure &gt; 140/90 mmHg 2 antihypertensive medication 4 . Myocardial infarction within 3 month prior start DCBBO1301 administration 5 . Prothrombin time &gt; 1.5 x ULN ; APTT abnormal ( &lt; 20 sec &gt; 34 sec ) ; long QT syndrome 12 . Significant gastrointestinal disorder ( ) would , opinion investigator , prevent absorption orally available agent 13 . Has receive investigational agent within 4 week enter study 14 . With condition judge investigator enter trial may detrimental subject 15 . Receiving chemotherapy , investigational hormonal therapy , major surgery previous 4 week Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>